Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Download Therapeutic Strategies In Egfr Mutant Lung Cancer full books in PDF, epub, and Kindle. Read online Therapeutic Strategies In Egfr Mutant Lung Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author : Yaxiong Zhang
Publisher : Frontiers Media SA
ISBN 13 : 2832503802
Total Pages : 239 pages
Book Rating : 4.8/5 (325 download)
Download or read book Therapeutic Strategies in EGFR Mutant Lung Cancer written by Yaxiong Zhang and published by Frontiers Media SA. This book was released on 2022-11-03 with total page 239 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Anthony Faber
Publisher : Academic Press
ISBN 13 : 0128228342
Total Pages : 150 pages
Book Rating : 4.1/5 (282 download)
Download or read book Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC written by Anthony Faber and published by Academic Press. This book was released on 2023-01-30 with total page 150 pages. Available in PDF, EPUB and Kindle. Book excerpt: Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. - Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented - Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors - Encompasses the current state of affairs in clinical trials to address resistance
Author : Neele Drobnitzky
Publisher :
ISBN 13 :
Total Pages : pages
Book Rating : 4.:/5 (16 download)
Download or read book Novel Therapeutic Strategies for Targeting EGFR Mutated Non-small Cell Lung Cancer written by Neele Drobnitzky and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Solange Peters
Publisher : Springer
ISBN 13 : 3319060627
Total Pages : 255 pages
Book Rating : 4.3/5 (19 download)
Download or read book New Therapeutic Strategies in Lung Cancers written by Solange Peters and published by Springer. This book was released on 2014-10-01 with total page 255 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides an up-to-date review of current management techniques for Non-Small Cell Lung Cancer. It addresses all of the latest issues that have been raised by the discovery of oncogenic drivers and the improvement of diagnosis and therapeutic methods, including new radiotherapy techniques and anticancer strategies like immunotherapy. New strategies for patients with molecular alterations and the management of particular types of cases are also highlighted. Written by recognized experts in their field, the book represents a unique and valuable resource in the field of lung cancer, both for those currently in training and for those already in clinical or research practice.
Author : Marianne Davies
Publisher : Springer
ISBN 13 : 3030165507
Total Pages : 120 pages
Book Rating : 4.0/5 (31 download)
Download or read book Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners written by Marianne Davies and published by Springer. This book was released on 2019-07-16 with total page 120 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.
Author : So Yeon Kim
Publisher : Cambridge University Press
ISBN 13 : 1009342320
Total Pages : 72 pages
Book Rating : 4.0/5 (93 download)
Download or read book EGFR-Directed Therapy in Lung Cancer written by So Yeon Kim and published by Cambridge University Press. This book was released on 2023-01-26 with total page 72 pages. Available in PDF, EPUB and Kindle. Book excerpt: Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).
Author : Yuichi Takiguchi
Publisher : Springer
ISBN 13 : 9811020027
Total Pages : 321 pages
Book Rating : 4.8/5 (11 download)
Download or read book Molecular Targeted Therapy of Lung Cancer written by Yuichi Takiguchi and published by Springer. This book was released on 2017-01-24 with total page 321 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.
Author : Umberto Malapelle
Publisher : Frontiers Media SA
ISBN 13 : 2889452638
Total Pages : 86 pages
Book Rating : 4.8/5 (894 download)
Download or read book Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs written by Umberto Malapelle and published by Frontiers Media SA. This book was released on 2017-08-29 with total page 86 pages. Available in PDF, EPUB and Kindle. Book excerpt: Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and in the population receiving the maintenance therapy over 16 months. Given these results, more than 60% of patients may receive a second line therapy with further opportunities to improve the length and quality of life. For patients not harbouring targetable DNA mutations newer options will be available for second line therapeutic schemes and two major assets seem to be promising: immune modulation and anti-angiogenetic agents. In particular, anti PD1/PDL1 antibodies, VEGFR antibodies and TKIs, these latter combined with standard chemotherapy docetaxel advance the median overall survival of 12 months. These drugs have a different mechanism of action, various adverse events and their activity is different depending on the types of population. However, the biomarkers’ activity and efficacy prediction are not fully or totally understood. In addition, also for patients with DNA targetable mutations new drugs seems to be promising for the use in the second line therapeutic protocols. In particular, drugs selectively directed against ALK translocation and mutational events and EGFR T790M secondary mutations seems to be very promising. In this Research Topic we critically discuss the older therapies and the historical development of second line, putting in to perspective the new agents available in clinical practice. We discuss their importance from a clinical point of view, but also consider and exploit the complex molecular mechanisms responsible of their efficacy or of the subsequently observed resistance phenomena. In this perspective, the undercovering and characterization of novel predictive biomarkers by NGS technology, the characterization of novel actors in the signal transduction pathway modulating the response of the cells, the optimization of new diagnostic tool as the evaluation of liquid biopsy and the implementation of more suitable pre-clinical models are crucial aspects dissected too. Nivolumab, nintedanib and ramucirumab probably will give the opportunity to improve the efficacy outcomes for the treatment of wild type tumours in second line therapeutic schemes, but many aspects should be debated in order that these agents are made available to patients, planning ahead a therapeutic strategy, beginning from the first line therapy, to the subsequent ones in a logical and affordable manner. As well, for treatment of mutated tumours, mutated EGFR irreversible inhibitors such as rociletinib and AZD9291, and ALK targeting drugs ceritinib and alectinib will also play an important role in the immediate future. Probably the right way is to give all the available opportunities to patients, but challenges and pitfalls should be carefully debated, and by launching this Research Topic we tried to give some practical insights in this changing landscape.
Author : Caroline Amalia Nebhan
Publisher :
ISBN 13 :
Total Pages : 145 pages
Book Rating : 4.:/5 (89 download)
Download or read book Acquired Resistance to Targeted Therapy in EGFR-mutant Lung Adenocarcinoma written by Caroline Amalia Nebhan and published by . This book was released on 2014 with total page 145 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Courtney A. Kurtyka
Publisher :
ISBN 13 :
Total Pages : 120 pages
Book Rating : 4.:/5 (11 download)
Download or read book Novel Therapeutic Strategies in Lung Cancer written by Courtney A. Kurtyka and published by . This book was released on 2014 with total page 120 pages. Available in PDF, EPUB and Kindle. Book excerpt: Lung cancer is the leading cause of cancer–related death and the second most diagnosed cancer in the United States. Unfortunately, many patients either do not have any common mutations for which there are already targetable agents, or they eventually become resistant to these compounds. As such, there is a high demand for new, effective methods of treating this disease as well as predicting patient prognosis and potential benefit from chemotherapy. In this work, numerous strategies for treating lung cancer are explored. The first method described here is through the use of a pan–early 2 factor (E2F) inhibitor, HLM006474, which is shown to synergize with paclitaxel in non–small cell lung cancer (NSCLC). Next, we explored the creation and utilization of an E2F signature that is prognostic and predictive of early–stage NSCLC patient benefit from adjuvant chemotherapy (ACT). The third project examined possible targets to enhance sensitivity to cisplatin in NSCLC lacking Kirsten rat sarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma receptor tyrosine kinase (ALK) fusions (“triple–negative”), for which cisplatin is one of the few treatment options. These studies led to the identification of a kinase that is overexpressed in NSCLC and whose knockdown sensitizes cells to platinum agents.
Author : Federico Cappuzzo
Publisher : Springer
ISBN 13 : 3319030590
Total Pages : 75 pages
Book Rating : 4.3/5 (19 download)
Download or read book Guide to Targeted Therapies: EGFR mutations in NSCLC written by Federico Cappuzzo and published by Springer. This book was released on 2014-09-25 with total page 75 pages. Available in PDF, EPUB and Kindle. Book excerpt: Guide to Targeted Therapies: EGFR Mutations in NSCLC is a speedy and up-to-date review, which discusses EGFR mutations, testing methods and technology, current and emerging therapies, and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of EGFR gene mutations as well as a summary of current therapies will benefit from this succinct guide.
Author : Catherine Belle Meador
Publisher :
ISBN 13 :
Total Pages : 228 pages
Book Rating : 4.:/5 (914 download)
Download or read book Optimizing the Sequence of Targeted Therapy in EGFR-mutant Lung Adenocarcinoma written by Catherine Belle Meador and published by . This book was released on 2015 with total page 228 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Ravi Salgia
Publisher : Springer
ISBN 13 : 3030178323
Total Pages : 238 pages
Book Rating : 4.0/5 (31 download)
Download or read book Targeted Therapies for Lung Cancer written by Ravi Salgia and published by Springer. This book was released on 2019-06-26 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
Author : Kamal Dua
Publisher : Springer Nature
ISBN 13 : 9813368276
Total Pages : 926 pages
Book Rating : 4.8/5 (133 download)
Download or read book Targeting Cellular Signalling Pathways in Lung Diseases written by Kamal Dua and published by Springer Nature. This book was released on 2021-07-02 with total page 926 pages. Available in PDF, EPUB and Kindle. Book excerpt: The book comprehensively reviews and provides detailed insight into the cellular and molecular signalling mechanisms involved in pathophysiology of various respiratory diseases, towards developing effective therapeutic strategies in the management and treatment of lung disease. It also covers promising advances in the field of therapeutics that could lead to novel clinical therapies capable of preventing or reversing the disease features including novel strategies for targeting chronic lung diseases using advanced drug delivery systems. Importantly, the book examines the significance and relevance of the plant extracts and their constituents with therapeutic efficiencies against lung diseases. As such, the book offers a blend of translational, biological, chemical, and drug delivery aspects relevant to respiratory diseases, thus, offering a valuable resource for pulmonologists and translational researchers working in the field of pulmonary biology and respiratory medicine.
Author : Ming Sound Tsao
Publisher :
ISBN 13 : 9780983295853
Total Pages : pages
Book Rating : 4.2/5 (958 download)
Download or read book IASLC Atlas of ALK and ROS1 Testing in Lung Cancer written by Ming Sound Tsao and published by . This book was released on 2016-12-04 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer is a resource designed to help pathologists, laboratory scientists, and practicing physicians better understand the background, protocol, and interpretation of results of ALK and ROS1 testing for patients with advanced non-small cell lung cancer.
Author : S. Peters
Publisher : Karger Medical and Scientific Publishers
ISBN 13 : 3318025429
Total Pages : 126 pages
Book Rating : 4.3/5 (18 download)
Download or read book Successes and Limitations of Targeted Cancer Therapy written by S. Peters and published by Karger Medical and Scientific Publishers. This book was released on 2014-02-19 with total page 126 pages. Available in PDF, EPUB and Kindle. Book excerpt: The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies.
Author : Philip T. Cagle
Publisher : Springer Science & Business Media
ISBN 13 : 1461431972
Total Pages : 217 pages
Book Rating : 4.4/5 (614 download)
Download or read book Molecular Pathology of Lung Cancer written by Philip T. Cagle and published by Springer Science & Business Media. This book was released on 2012-06-14 with total page 217 pages. Available in PDF, EPUB and Kindle. Book excerpt: As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.
